A new method for targeted drug delivery using polymeric microcapsules
- 205 Downloads
Recent research and clinical evidence suggest that thalidomide could potentially be used to treat inflammation associated with Crohn's disease. However, systemic side effects associated with large doses of this drug have limited its widespread use. Treatment, with thalidomide would prove more efficacious if the drug could be delivered directly to target areas in the gut, thereby reducing systemic circulation. Microcapsule encapsulation could enable direct delivery of the drug. To assess the latter, we designed and tested drug-targeting release characteristics of alginate-poly-l-lysine-alginate (APA) microcapsules in simulated gastrointestinal environments. The results show that APA capsules enabled delivery of thalidomide in the middle and distal portions of the small intestine. We also compared the APA membrane formulation with an earlier designed alginate chitosan (AC) membrane thalidomide formulation. The results show that both APA and AC capsules allow for successful delivery of thalidomide in the gut and could prove beneficial in the treatment of Crohn's disease. However, further research is required.
Index EntriesThalidomide Crohn's disease artificial cells microcapsule inflammatory bowel disease
Unable to display preview. Download preview PDF.
- 9.Gardner-Medwin, J. M., Smith, N. J., and Powell, R. J. (1994) Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann. Rheum. Dis. 53, 828–832.PubMedGoogle Scholar
- 12.Sabate, J. M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M., and Modigliani, R. (2002) An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment. Pharmacol. Ther. 16, 1117–1124.PubMedCrossRefGoogle Scholar
- 17.Valero, F. C. and Gonzalez, V. B. (2002) Lung toxicity due to thalidomide. Arch. Bronconeumol. 38, 492–494.Google Scholar
- 23.Metz, T. (2003) Polymer microcapsules for targeted oral drug delivery in Crohn's disease. Ann. Can. Biomater. Soc. 1, 89.Google Scholar
- 24.Metz, T., Amre, D., Chen, H., Ouyang, W., Haque, T., Martoni, C., and Prakash, S. (2004) Artificial cells containing thalidomide as an alternative oral therapy method for Crohn's disease. Gastroenterology 126, A288.Google Scholar
- 29.Sabate, J. M., Villarejo, J., Lemann, M., Bonnet, J., Allez, M., and Modigliani, R. (2002) An openlabel study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment. Pharmacol. Ther. 16, 1117–1124.PubMedCrossRefGoogle Scholar